Acrivon Therapeutics, Inc.
ACRV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001781174
In the last 90 days, Acrivon Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 46 institutions reported holding it in 13F filings for Q2 2026, worth $38.1M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Acrivon Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 53 | 48 | −5 |
| Shares | 17.8M | 17.5M | −279.4K (−1.6%) |
| Value | $21.2M | $31.7M | +$10.5M (+49.5%) |
New holders (6)
Institutions that held Acrivon Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Acadian Asset Management LLC | 92,004 | $165.0K | 0.00% |
| Algert Global LLC | 44,648 | $80.8K | 0.00% |
| Bluefin Capital Management, LLC | 42,039 | $76.1K | 0.03% |
| AAFCPAs Wealth Management, LLC | 10,678 | $19.3K | 0.01% |
| EverSource Wealth Advisors, LLC | 373 | $675 | 0.00% |
| Colony Group, LLC | 19,846 | – | – |
Sold out (11)
Institutions that held Acrivon Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Jacobs Levy Equity Management, Inc | 382,234 | $454.9K |
| HRT Financial LP | 145,895 | $173.0K |
| Charles Schwab Investment Management Inc | 63,636 | $75.7K |
| Susquehanna International Group, LLP | 43,860 | $52.2K |
| AQR Capital Management LLC | 22,252 | $26.5K |
| Quadrature Capital Ltd | 22,175 | $26.3K |
| SG Americas Securities, LLC | 15,265 | $18.0K |
| Qube Research & Technologies Ltd | 12,692 | $15.1K |
| Ground Swell Capital, LLC | 12,215 | $14.5K |
| True Wealth Design, LLC | 176 | $210 |
| Wells Fargo & Company | 141 | $168 |